Market Signal Briefing

Decades of Cross-Cloud Expertise Bolstered by Global Scale, Promising Enhanced Project Support and Breakthrough Personalized Experiences

, /PRNewswire/ -- ListEngage has entered into an agreement to join Tata Consultancy Services (TCS). The acquisition became public on October 9, 2025, with TCS approving a 100% stake in ListEngage for $72.8 million. ListEngage is a Salesforce consultancy focused on enabling emerging technologies and digital transformation with a keen focus on Marketing Cloud, Data Cloud, Agentforce, and Salesforce CRM solutioning.

The fully remote Summit Salesforce partner, ListEngage, sees this acquisition as a testament to the longtime company value proposition of placing expertise, growth, and culture above all else. ListEngage Founder and CEO, Altaf Shaikh, emphasized this philosophy, stating, "I've always said, talent over location, and culture over talent." ListEngage customers can expect greater scale for project support and more innovation than ever before, said Altaf Shaikh.

"ListEngage complements TCS' existing capabilities in customer experience and digital transformation. With this new team, and ListEngage's strong market coverage, we expect to scale delivery and unlock new efficiencies through our global delivery model. TCS remains fully committed to supporting existing customers, ensuring continuity and excellence in service delivery," said Vikram Karakoti, Tata Consultancy Services, Global Head, Enterprise Solutions.

ListEngage adds more than 400 Salesforce certifications across more than 100 employees. ListEngage's deep expertise in AI-led marketing automation, cross-cloud data integration, and personalized marketing created a fantastic opportunity for a growth platform.

"Joining TCS means a lot of great things, but most of all - it means we're going to have a greater capacity to serve our customers," said Bryan da Frota, ListEngage COO.

ListEngage will now join TCS's global workforce of over 600,000 employees. Bryan da Frota also noted the complementary cultures, remarking, "Our ability to service companies just got multiplied and bolstered by a company that not only has the incredible capabilities, but incredible culture to match our own." This strategic acquisition bolsters TCS's focus on AI and intelligent automation.

"By bringing together TCS's global scale with ListEngage's Salesforce and AI expertise, we're creating a powerhouse that will redefine how enterprises harness data, cloud, and AI to drive meaningful business outcomes," said Altaf Shaikh.

This acquisition "opens a world of opportunity to scale and innovate even more with AI," within the Salesforce ecosystem, according to Pratik Desai, ListEngage Head of Applied AI. Desai further expressed his excitement for the future, stating, "I've been in the Salesforce ecosystem for more than 10 years, and I can honestly say I've never been more excited for what's next."

The enhanced capacity is crucial for supporting cutting-edge technologies like Agentforce, Salesforce's digital labor platform. ListEngage is already recognized as a critical partner for identifying and developing specific use cases for joint customers across industries, helping to ensure tailored and effective AI solutions for scaling digital labor. Through this acquisition, ListEngage now has greater scale. "This is like adding rocket fuel to our team, leading the charge on emerging technologies, innovations, and AI," said Pratik Desai.

ListEngage has been on a growth trajectory since its inception in 2003, continuously increasing its practice size and disciplines across the ecosystem of Salesforce solutions. ListEngage Founder & CEO, Altaf Shaikh, takes pride in having built a company that scales across the clouds, including Salesforce Marketing Cloud, Data Cloud, Agentforce, CRM, and beyond.

"Our people are what make our company great. They're how we've gotten this far - coming from a small group of five in 2003, to where we are now, it's been an amazing journey. This is going to be our best chapter yet," said Altaf Shaikh.

For more information about ListEngage, visit www.listengage.com

ListEngage's Salesforce-certified and accredited experts guide your business to get the most out of AI-led marketing automation, cross-cloud data integration, and personalized marketing. With top-tier expertise across Marketing Cloud, Data Cloud, Agentforce and CRM, embark on your Salesforce Journey with a cross-cloud consulting partner who's done it all, from platform onboarding to large digital transformations and platform migration. As a Salesforce Ventures-backed, Summit status partner, customer success is at the heart of everything ListEngage accomplishes. ListEngage has supported 5,000+ successful projects and over 3,000 happy customers since inception in 2003.

Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS) is a digital transformation and technology partner of choice for industry-leading organizations worldwide. Since its inception in 1968, TCS has upheld the highest standards of innovation, engineering excellence and customer service.

Rooted in the heritage of the Tata Group, TCS is focused on creating long term value for its clients, its investors, its employees, and the community at large. With a highly skilled workforce spread across 55 countries and 202 service delivery centers across the world, the company has been recognized as a top employer in six continents. With the ability to rapidly apply and scale new technologies, the company has built long term partnerships with its clients – helping them emerge as perpetually adaptive enterprises. Many of these relationships have endured into decades and navigated every technology cycle, from mainframes in the 1970s to Artificial Intelligence today.

TCS sponsors 14 of the world's most prestigious marathons and endurance events, including the TCS New York City Marathon, TCS London Marathon and TCS Sydney Marathon with a focus on promoting health, sustainability, and community empowerment.

TCS generated consolidated revenues of over US $30 billion in the fiscal year ended March 31, 2025. For more information, visit www.tcs.com

SOURCE ListEngage

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Investors should monitor Nvidia's competitive landscape closely.

Nvidia (NVDA -4.33%) continues to be a key enabler of the global artificial intelligence (AI) infrastructure buildout, with over 94% share of the discrete GPU market in the second quarter of 2025. Its Blackwell architecture chips, Compute Unified Device Architecture (CUDA) software stack, and AI-optimized networking solutions together form a formidable competitive moat.

The company's commitment to innovation -- releasing new hardware architectures annually while maintaining backward compatibility -- has increased customer loyalty. Unsurprisingly, demand for the company's GPUs from hyperscalers and enterprise AI giants has consistently outpaced available supply.

Image source: Getty Images.

Nvidia's dominance, however, may face serious challenges in 2026. Increasing competitive and geopolitical pressures, along with a rising focus on cost-effectiveness, may affect the company's topline and bottom-line growth prospects in the coming year. Here's how I believe these problems could evolve in 2026.

Competitive pressures
The biggest challenge for Nvidia is the rapid emergence of alternatives to its GPUs, both from competitors offering chips with superior price performance and large clients developing proprietary silicon for specialized AI workloads.

While still far behind in the discrete GPU market share, competitor Advanced Micro Devices (AMD 0.80%) is gearing up for the launch of Instinct MI450 series GPUs in 2026. These GPUs are based on CDNA 5 architecture and are built using Taiwan Semiconductor Manufacturing's (also known as TSMC) advanced 2-nanometer process technology. The MI450 series is expected to emerge as direct competition not only to Nvidia's Hopper and Blackwell GPUs, but also to the upcoming Rubin architecture GPUs built on 3-nanometer process technology.

AMD's recent strategic partnership with OpenAI underlines the confidence in this new AI chip. According to this multi-year and multi-generation partnership, OpenAI will deploy 6 gigawatts of AMD Instinct GPUs. The first 1 gigawatt deployment based on MI450 GPUs will commence in the second half of 2026. With the deal positioning AMD as a core compute supplier for OpenAI's next-generation frontier models, AMD CEO Lisa Su expects to generate tens of billions of dollars in annual AI data-center revenue starting in 2027. AMD estimates this collaboration, along with other large customer deployments, could eventually generate over $100 billion in revenue in the next few years.

CEO Lisa Su also claimed that AMD's chiplet-based GPU architecture (a processor made of several small chips) offers substantial advantages in memory capacity and bandwidth, which can be crucial for inference workloads. As hyperscalers push for unified infrastructure that can handle both training and inference, AMD's upcoming MI450 GPUs are being designed to serve both workloads efficiently.

AMD's increasing technological prominence in the GPU market poses a significant challenge to Nvidia's supremacy.

Broadcom's custom application-specific integrated circuits (ASICs) and other accelerators are also being increasingly adopted at hyperscaler data centers. Major cloud players such as Meta Platforms, Microsoft, Amazon, and Alphabet have also developed custom silicon, which reduces their reliance on Nvidia. Alphabet's Tensor Processing Units (TPUs) and Amazon's Inferentia chips already deliver better performance at a lower cost in specific training and inferencing tasks. As more hyperscalers scale these in-house solutions and partner with other semiconductor players, it could adversely impact Nvidia's share of the AI compute spending.

Cost advantages
AMD's competitive pricing may soon become a key differentiator, especially since the target addressable market for AI accelerators is now projected to surpass $500 billion by 2028. AMD claims that its MI355 accelerator (from the MI350 series accelerators) has demonstrated matching or better performance than Nvidia's Blackwell architecture-based GB200 chips for specific key training and inference workloads. MI355 was also said to deliver performance matching to that of GB200 for specific other workloads at a lower cost and capacity.

According to Dell'Oro Group, global data center capex is estimated to reach $1.2 trillion by 2029. Hyperscalers are expected to account for nearly half of this spend. Faced with escalating infrastructure and energy costs, cloud giants are exploring lower-cost accelerators to reduce the total cost of ownership while ensuring high performance. In this backdrop, AMD's competitively priced Instinct accelerators could prove to be an appealing alternative for hyperscalers. This may even pressure Nvidia to take some pricing cuts to protect its market share.

Geopolitical and Supply Chain Pressures
Nvidia's excessive reliance on TSMC's foundries has exposed it to significant geopolitical and supply chain disruption risk, considering that Taiwan is just roughly 100 miles from mainland China. The escalating U.S.-China tensions have already negatively impacted the company's chip exports to China.

In July 2025, China's internet regulator, The Cyberspace Administration of China summoned Nvidia to explain the alleged security vulnerabilities in its H20 chips. Chinese authorities have also intensified customs inspections of Nvidia's AI chip imports, to reduce reliance on U.S. imports as of October 2025. According to Reuters, China's crackdown was initially focused on China-specific models like the H20 and RTX Pro 6000D. However, it has now been expanded to include all advanced semiconductor products that could fall under U.S. export restrictions. These events have negatively impacted the company's sales in the key Chinese market.

The heightened geopolitical tensions have also spurred countries around the world to focus on localizing the semiconductor supply chain. Several incentives are being offered to semiconductor manufacturers under the U.S. CHIPS Act and similar programs in Europe and Japan. TSMC, Samsung, and Intel are building new foundries in the U.S., Europe, and Asia.

While these foundries are not Nvidia's direct competitors, expansion of manufacturing capacity will help competitors such as AMD, Intel, and Broadcom, as well as hyperscalers designing custom AI silicon to scale production efficiently. This may erode Nvidia's supply advantage in the long run.

Premium valuation
Nvidia trades at a premium valuation of 28.5 times forward earnings. However, in the face of increasing adoption of open hardware ecosystems and alternative AI chips, the company may witness compression in valuation multiples. Coupled with potential margin compression and slower topline growth, these factors may weigh on the company's share prices in 2026.

While none of these risks are certain to materialize, investors should remain vigilant about market share shifts and cost-sensitive deployments across the AI landscape. These are tangible risks, and Nvidia has to navigate them carefully to sustain its growth trajectory beyond 2026.

Manali Pradhan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices, Alphabet, Amazon, Intel, Meta Platforms, Microsoft, Nvidia, and Taiwan Semiconductor Manufacturing. The Motley Fool recommends Broadcom and recommends the following options: long January 2026 $395 calls on Microsoft, short January 2026 $405 calls on Microsoft, and short November 2025 $21 puts on Intel. The Motley Fool has a disclosure policy.

, /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that VEOZAH™ (fezolinetant), its first-in-class, targeted, non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) due to menopause, will be featured in six Astellas-sponsored poster presentations during The Menopause Society 2025 Annual Meeting in Orlando, Florida, October 21-25. VMS, also known as hot flashes and/or night sweats, are common symptoms of menopause.1,2

The presentations, which feature three Late Breaking Abstracts (LBA), will include two preliminary analyses from the OPTION-VMS study. These analyses evaluate, in a real-world setting, both the changes in the impact VMS among women beginning non-hormonal therapy (non-HT) for VMS and the effects on work productivity for women initiating non-HT to manage these symptoms. These results highlight Astellas' commitment to expanding clinical knowledge about VEOZAH beyond the pivotal trials to help improve the lives of all those impacted by VMS due to menopause.

Karla Martins, Executive Medical Director for Global Medical Affairs, Astellas
"Astellas is dedicated to expanding the clinical understanding of our medicines. We are pleased to share comprehensive data on fezolinetant at this year's TMS meeting. These results provide further evidence of the efficacy and safety of fezolinetant as a treatment option for moderate to severe VMS due to menopause."

Fezolinetant data to be presented as posters during the 2025 Annual Meeting of The Menopause Society include:

OPTION-VMS: Preliminary Analysis of a Phase IV Observational, Real-World Study of Non-hormonal Pharmacotherapies for Bothersome Menopause-Associated Vasomotor Symptoms [Abstract ID: 4380798 / Poster #: P-127, Genevieve Neal-Perry, Samuel Lederman, Shayna Mancuso, Arianne Schild, Michele Helbing, Aki Shiozawa, Karla Martins, Pauline Maki, Rebecca Thurston]
Preliminary Analysis of Work Productivity Outcomes in OPTION-VMS: A Phase IV Observational, Real-World Study of Non-hormonal Treatment for Bothersome Menopause-Associated Vasomotor Symptoms [Abstract ID: 4380913 / Poster #: P-108, Pauline Maki, Shayna Mancuso, Michele Helbing, Arianne Schild, Karla Martins, Genevieve Neal-Perry, Rebecca Thurston]
A Matching-Adjusted Indirect Comparison of Fezolinetant and Elinzanetant for the Treatment of Vasomotor Symptoms Due to Menopause [Abstract ID: 4343203/ Poster #: P-154, Maria Shapiro, Petra Stute, Antonia Morga, Ting-an Tai, Mayank Ajmera, Bogdan Muresan, Karla Martins, Yechu Hua, Angela Zhao, Jingyi Liu, Rossella Nappi]
Prior Treatment Patterns and Healthcare Resource Utilization of Individuals Who Received Fezolinetant Treatment: A Claims Database Analysis [Abstract ID: 4308801 / Poster #: P-38, Barbara DePree, Mayank Ajmera, Valery Walker, Hannah Clark, Di Zhao, Christina Steiger, Michele Helbing]
Vasomotor Symptoms Due to Menopause after Treatment Discontinuation in Phase 3 Fezolinetant SKYLIGHT Studies [Abstract ID: 4342174 / Poster #: P-128, Genevieve Neal-Perry, Petra Stute, Karla Martins, Arianne Schild, Xuegong Wang, Rossella Nappi]
Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause in Participants with Medical Comorbidities: Pooled Analysis of Three 52-Week Phase 3 Studies (SKYLIGHT 1, 2, and 4) [Abstract ID: 4342237 / Poster #: P-158, Andrea Singer, Michele Helbing, Arianne Schild, Kaitlin Montagano, Karla Martins, Risa Kagan, Antonio Cano]

An additional poster presentation will highlight results from a survey to understand factors contributing to healthcare and treatment perceptions for menopause and related VMS among non-Hispanic/Latino black or African American women in the US.

Posters will be presented on Thursday, October 23, 6:15 – 7:15 PM.

About OPTION-VMS
OPTION-VMS (NCT06049797) is an ongoing Phase IV, longitudinal, observational, study on women aged 40-75 years with confirmed menopausal VMS who were prescribed a non-hormonal therapy (non-HT) for the treatment of bothersome VMS by their healthcare provider in a real-world setting. The primary objective of the study is to evaluate the change in VMS bother in women; additional outcomes include sleep quality, menopause-related quality of life, sexual health, mood and work productivity. A total of 998 women were enrolled at 50 sites in the U.S.

About the BRIGHT SKY™ Phase 3 Program
The BRIGHT SKY pivotal trials, SKYLIGHT 1™ (NCT04003155) and SKYLIGHT 2™ (NCT04003142), enrolled over 1,000 menopausal women with moderate to severe VMS. The trials are double-blinded, placebo-controlled for the first 12 weeks followed by a 40-week treatment extension period. Women were enrolled at over 180 sites within the U.S., Canada and Europe. SKYLIGHT 4™ (NCT04003389) is a 52-week double-blinded, placebo-controlled study designed to investigate the long-term safety of fezolinetant. For SKYLIGHT 4, over 1,800 menopausal women with VMS were enrolled at over 180 sites within the U.S., Canada and Europe.

About VEOZAH™ (fezolinetant)
VEOZAH (fezolinetant) is a nonhormonal neurokinin 3 (NK3) receptor antagonist indicated in the United States for the treatment of moderate to severe vasomotor symptoms (hot flashes and night sweats) due to menopause. VEOZAH works by blocking neurokinin B (NKB) binding on the kisspeptin/neurokinin/ dynorphin (KNDy) neuron to modulate neuronal activity in the brain's temperature control center (the hypothalamus) to reduce the frequency and severity of moderate to severe VMS due to menopause 3,4,5

U.S. Important Safety Information

VEOZAH can cause serious side effects, including: 

Liver Problems. Your healthcare provider will do a blood test to check your liver before you start taking VEOZAH. Your healthcare provider will also do this blood test monthly for the first 3 months, at month 6, and month 9 after you start taking VEOZAH or if you have signs or symptoms that suggest liver problems. If your liver blood test values are elevated, your healthcare provider may advise you to stop treatment or request additional liver blood tests.

Stop VEOZAH right away and call your healthcare provider if you have the following signs or symptoms of liver problems: 

feeling more tired than you do usually
decreased appetite
nausea
vomiting
itching
yellowing of the eyes or skin (jaundice)
pale feces
dark urine
pain in the stomach (abdomen)

Do not use VEOZAH if you: 

have cirrhosis.
have severe kidney problems or kidney failure.
are taking certain medicines called CYP1A2 inhibitors. Ask your healthcare provider if you are not sure.

Before you use VEOZAH, tell your healthcare provider about all your medical conditions, including if you: 

have liver disease or problems.
have kidney problems.
have any medical conditions that may become worse while you are using VEOZAH.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VEOZAH may affect the way other medicines work, and other medicines may affect how VEOZAH works.

The most common side effects of VEOZAH include: 

stomach (abdominal) pain
diarrhea
difficulty sleeping (insomnia)
back pain
hot flashes or hot flushes

These are not all the possible side effects of VEOZAH. Tell your healthcare provider if you have any side effect that bothers you or does not go away.

Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For more information, please see the full Prescribing Information and Patient Product Information for VEOZAH (fezolinetant).

About Astellas
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com.

Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

References:

1 Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes. 2005;3:47.

2 Jones RE, Lopez KH, eds. Human Reproductive Biology. 4th ed. Waltham, MA: Elsevier, 2014:120.

3 Depypere H, Timmerman D, Donders G, et al. Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial. J Clin Endocrinol Metab. 2019;104:5893-5905.

4 Fraser GL, Lederman S, Waldbaum A, et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause. 2020;27:382-392. 

5 Fraser GL, Hoveyda HR, Clarke IJ, et al. The NK3 receptor antagonist ESN364 interrupts pulsatile LH secretion and moderate levels of ovarian hormones throughout the menstrual cycle. Endocrinology. 2015;156:4214-4225. 

SOURCE Astellas Pharma Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Hilary Kramer looks at payment stocks; she likes Klarna (KLAR) because of its relationship with Amazon (AMZN), and Jefferson Capital (JCAP). In energy, she likes Oklo (OKLO), citing pressures on the grid.

As two of the most prominent asset managers, BlackRock (BLK - Free Report)  and Goldman Sachs (GS - Free Report)  helped highlight Tuesday’s Q3 earnings lineup after exceeding their quarterly expectations and hitting records in assets under management (AUM).

Notably, both firms are benefiting from strong inflows across asset classes and strategic positioning in high-growth areas like passive investing and digital finance.   

BlackRock shares were nicely up over +3% in today’s trading session, with BLK extending to year-to-date gains of +18% while Goldman Sachs stock dipped 2% on what appears to be some profit taking as GS is still up an impressive +37% YTD.

Image Source: Zacks Investment Research

BlackRock & Goldman Sachs Q3 ResultsPosting Q3 sales of $6.5 billion, BlackRock’s top line expanded 25% from $5.19 billion in the prior year quarter and topped estimates of $6.24 billion. BlackRock’s Q3 earnings were up nearly 1% to $11.55 per share, beating EPS expectations of $11.19 by 3%.

Pivoting to Goldman Sachs, Q3 sales of $15.18 billion stretched 19% from $12.69 billion a year ago and noticeably exceeded estimates of $14.14 billion by 7%. More impressive, Goldman Sachs' Q3 EPS climbed nearly 46% to $12.25 compared to $8.40 per share in the comparative quarter and beat expectations of $11.11 by 10%.

BlackRock & Goldman Sachs Record AUMRemaining the largest global asset manager, BlackRock’s AUM spiked 17% year over year to a record $13.5 trillion.

Placing among the top 10 largest asset managers globally, Goldman Sachs' AUM also hit a new peak of $3.45 trillion, rising 11% YoY.

BLK & GS Valuation ComparisonGoldman Sachs' valuation stands out at 16X forward earnings. In this regard, GS trades at a distinct discount to the benchmark S&P 500’s 25X forward earnings multiple, with BlackRock at 24X.

GS also trades near the preferred level of less than 2X forward sales, with BLK at 8X and trading at a premium to the S&P 500’s 5X.

Image Source: Zacks Investment Research

BLK & GS Dividend ComparisonOffering respectable dividends, Goldman Sachs' current yield of 2.03% edges BlackRock’s 1.8%. These yields top the S&P 500’s 1.11% average, although BlackRock’s slightly trails the broader Zacks financial sector’s 1.89%.

Image Source: Zacks Investment Research

Should Investors Buy BLK or GS Stock?Despite having the advantage in AUM, BlackRock stock pales in comparison to Goldman Sachs in many metrics. However, both of these prominent finance stocks have proven to be viable investments in the portfolio, and for now, they land a Zacks Rank #3 (Hold), respectively.

That said, a buy rating could certainly be on the way for Goldman Sachs, as earnings estimate revisions are likely to rise in the coming weeks, given its impressive Q3 EPS beat. 

Cadence Design Systems (CDNS - Free Report) closed the most recent trading day at $325.75, moving -1.95% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.16%. At the same time, the Dow added 0.44%, and the tech-heavy Nasdaq lost 0.76%.

Shares of the maker of hardware and software products for validating chip designs have depreciated by 5.49% over the course of the past month, underperforming the Computer and Technology sector's gain of 3.34%, and the S&P 500's gain of 1.14%.

The investment community will be closely monitoring the performance of Cadence Design Systems in its forthcoming earnings report. The company is scheduled to release its earnings on October 27, 2025. On that day, Cadence Design Systems is projected to report earnings of $1.79 per share, which would represent year-over-year growth of 9.15%. Our most recent consensus estimate is calling for quarterly revenue of $1.32 billion, up 8.96% from the year-ago period.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $6.91 per share and revenue of $5.25 billion, indicating changes of +15.75% and +13.06%, respectively, compared to the previous year.

Investors might also notice recent changes to analyst estimates for Cadence Design Systems. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. As of now, Cadence Design Systems holds a Zacks Rank of #2 (Buy).

In terms of valuation, Cadence Design Systems is currently trading at a Forward P/E ratio of 48.11. This valuation marks a premium compared to its industry average Forward P/E of 27.49.

Also, we should mention that CDNS has a PEG ratio of 3.45. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Computer - Software was holding an average PEG ratio of 2.06 at yesterday's closing price.

The Computer - Software industry is part of the Computer and Technology sector. This industry, currently bearing a Zacks Industry Rank of 80, finds itself in the top 33% echelons of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

CyberArk (CYBR - Free Report) closed at $491.30 in the latest trading session, marking a -2.52% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.16%. On the other hand, the Dow registered a gain of 0.44%, and the technology-centric Nasdaq decreased by 0.76%.

Shares of the maker of software that detects attacks on privileged accounts witnessed a gain of 5.9% over the previous month, beating the performance of the Computer and Technology sector with its gain of 3.34%, and the S&P 500's gain of 1.14%.

The investment community will be closely monitoring the performance of CyberArk in its forthcoming earnings report. On that day, CyberArk is projected to report earnings of $0.92 per share, which would represent a year-over-year decline of 2.13%. Alongside, our most recent consensus estimate is anticipating revenue of $327.05 million, indicating a 36.21% upward movement from the same quarter last year.

CYBR's full-year Zacks Consensus Estimates are calling for earnings of $3.86 per share and revenue of $1.33 billion. These results would represent year-over-year changes of +27.39% and +32.53%, respectively.

Any recent changes to analyst estimates for CyberArk should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 66.92% lower. CyberArk is currently a Zacks Rank #4 (Sell).

Digging into valuation, CyberArk currently has a Forward P/E ratio of 130.72. For comparison, its industry has an average Forward P/E of 70.9, which means CyberArk is trading at a premium to the group.

It is also worth noting that CYBR currently has a PEG ratio of 5.38. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Security industry was having an average PEG ratio of 2.82.

The Security industry is part of the Computer and Technology sector. At present, this industry carries a Zacks Industry Rank of 211, placing it within the bottom 15% of over 250 industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Albertsons Companies, Inc. (ACI - Free Report) reported $18.92 billion in revenue for the quarter ended August 2025, representing a year-over-year increase of 2%. EPS of $0.44 for the same period compares to $0.51 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $18.9 billion, representing a surprise of +0.1%. The company delivered an EPS surprise of +12.82%, with the consensus EPS estimate being $0.39.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Albertsons Companies performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Same - Store Sales (Identical sales): 2.2% compared to the 2% average estimate based on five analysts.Number of stores at end of quarter: 2,257 versus 2,267 estimated by four analysts on average.Total Square Footage - Retail Square Feet: 112.5 million compared to the 112.93 million average estimate based on three analysts.Revenues- Fuel: $911.3 million versus $951.3 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -4.2% change.View all Key Company Metrics for Albertsons Companies here>>>

Shares of Albertsons Companies have returned -7.9% over the past month versus the Zacks S&P 500 composite's +1.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Kroger (KR - Free Report) ended the recent trading session at $69.13, demonstrating a +2.98% change from the preceding day's closing price. This change outpaced the S&P 500's 0.16% loss on the day. On the other hand, the Dow registered a gain of 0.44%, and the technology-centric Nasdaq decreased by 0.76%.

Prior to today's trading, shares of the supermarket chain had lost 0.42% was narrower than the Retail-Wholesale sector's loss of 4.08% and lagged the S&P 500's gain of 1.14%.

Market participants will be closely following the financial results of Kroger in its upcoming release. In that report, analysts expect Kroger to post earnings of $1.04 per share. This would mark year-over-year growth of 6.12%. In the meantime, our current consensus estimate forecasts the revenue to be $34.31 billion, indicating a 2.02% growth compared to the corresponding quarter of the prior year.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.79 per share and a revenue of $148.79 billion, indicating changes of +7.16% and +1.13%, respectively, from the former year.

Any recent changes to analyst estimates for Kroger should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.13% higher. Kroger presently features a Zacks Rank of #3 (Hold).

In terms of valuation, Kroger is presently being traded at a Forward P/E ratio of 14.03. This represents a discount compared to its industry average Forward P/E of 16.94.

Investors should also note that KR has a PEG ratio of 1.95 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. KR's industry had an average PEG ratio of 2.39 as of yesterday's close.

The Retail - Supermarkets industry is part of the Retail-Wholesale sector. This group has a Zacks Industry Rank of 157, putting it in the bottom 37% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Oscar Health, Inc. (OSCR - Free Report) ended the recent trading session at $20.69, demonstrating a +1.42% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily loss of 0.16%. Elsewhere, the Dow gained 0.44%, while the tech-heavy Nasdaq lost 0.76%.

Shares of the company witnessed a gain of 8.92% over the previous month, beating the performance of the Finance sector with its loss of 1.81%, and the S&P 500's gain of 1.14%.

The investment community will be closely monitoring the performance of Oscar Health, Inc. in its forthcoming earnings report. The company is scheduled to release its earnings on November 6, 2025. In that report, analysts expect Oscar Health, Inc. to post earnings of -$0.55 per share. This would mark a year-over-year decline of 150%. Alongside, our most recent consensus estimate is anticipating revenue of $3.09 billion, indicating a 27.51% upward movement from the same quarter last year.

OSCR's full-year Zacks Consensus Estimates are calling for earnings of -$1.42 per share and revenue of $12.06 billion. These results would represent year-over-year changes of -1520% and +31.44%, respectively.

It is also important to note the recent changes to analyst estimates for Oscar Health, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. At present, Oscar Health, Inc. boasts a Zacks Rank of #3 (Hold).

The Insurance - Multi line industry is part of the Finance sector. This industry currently has a Zacks Industry Rank of 76, which puts it in the top 31% of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.

In the latest close session, Kraft Heinz (KHC - Free Report) was up +1.31% at $25.44. This change outpaced the S&P 500's 0.16% loss on the day. Meanwhile, the Dow experienced a rise of 0.44%, and the technology-dominated Nasdaq saw a decrease of 0.76%.

Prior to today's trading, shares of the processed food company with dual headquarters in Pittsburgh and Chicago had lost 2.03% was narrower than the Consumer Staples sector's loss of 3.79% and lagged the S&P 500's gain of 1.14%.

Analysts and investors alike will be keeping a close eye on the performance of Kraft Heinz in its upcoming earnings disclosure. The company's earnings report is set to go public on October 29, 2025. The company's upcoming EPS is projected at $0.57, signifying a 24.00% drop compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $6.27 billion, down 1.79% from the year-ago period.

For the full year, the Zacks Consensus Estimates are projecting earnings of $2.57 per share and revenue of $25.25 billion, which would represent changes of -16.01% and -2.31%, respectively, from the prior year.

Investors might also notice recent changes to analyst estimates for Kraft Heinz. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.3% lower within the past month. Right now, Kraft Heinz possesses a Zacks Rank of #4 (Sell).

In the context of valuation, Kraft Heinz is at present trading with a Forward P/E ratio of 9.76. This denotes a discount relative to the industry average Forward P/E of 15.51.

It's also important to note that KHC currently trades at a PEG ratio of 2.94. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. KHC's industry had an average PEG ratio of 1.68 as of yesterday's close.

The Food - Miscellaneous industry is part of the Consumer Staples sector. This industry currently has a Zacks Industry Rank of 195, which puts it in the bottom 22% of all 250+ industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow KHC in the coming trading sessions, be sure to utilize Zacks.com.

Hyster-Yale (HY - Free Report) closed at $36.14 in the latest trading session, marking a +1.89% move from the prior day. This change outpaced the S&P 500's 0.16% loss on the day. Meanwhile, the Dow gained 0.44%, and the Nasdaq, a tech-heavy index, lost 0.76%.

Coming into today, shares of the maker of lift trucks and aftermarket parts had lost 1.47% in the past month. In that same time, the Industrial Products sector lost 0.75%, while the S&P 500 gained 1.14%.

The upcoming earnings release of Hyster-Yale will be of great interest to investors. On that day, Hyster-Yale is projected to report earnings of $0.03 per share, which would represent a year-over-year decline of 96.91%. In the meantime, our current consensus estimate forecasts the revenue to be $955.69 million, indicating a 5.95% decline compared to the corresponding quarter of the prior year.

For the full year, the Zacks Consensus Estimates project earnings of $0.75 per share and a revenue of $3.77 billion, demonstrating changes of -91.65% and -12.59%, respectively, from the preceding year.

Investors should also take note of any recent adjustments to analyst estimates for Hyster-Yale. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Right now, Hyster-Yale possesses a Zacks Rank of #3 (Hold).

In terms of valuation, Hyster-Yale is presently being traded at a Forward P/E ratio of 47.29. This indicates a premium in contrast to its industry's Forward P/E of 19.57.

The Manufacturing - Construction and Mining industry is part of the Industrial Products sector. Currently, this industry holds a Zacks Industry Rank of 204, positioning it in the bottom 18% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Booz Allen Hamilton (BAH - Free Report) closed at $97.80 in the latest trading session, marking a +1.57% move from the prior day. This move outpaced the S&P 500's daily loss of 0.16%. Elsewhere, the Dow gained 0.44%, while the tech-heavy Nasdaq lost 0.76%.

The defense contractor's shares have seen a decrease of 5.25% over the last month, not keeping up with the Business Services sector's loss of 3.78% and the S&P 500's gain of 1.14%.

The investment community will be closely monitoring the performance of Booz Allen Hamilton in its forthcoming earnings report. The company is scheduled to release its earnings on October 24, 2025. The company is forecasted to report an EPS of $1.51, showcasing a 16.57% downward movement from the corresponding quarter of the prior year. At the same time, our most recent consensus estimate is projecting a revenue of $2.99 billion, reflecting a 5.09% fall from the equivalent quarter last year.

Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $6.33 per share and revenue of $12.13 billion. These totals would mark changes of -0.31% and +1.22%, respectively, from last year.

It is also important to note the recent changes to analyst estimates for Booz Allen Hamilton. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.47% lower. Booz Allen Hamilton presently features a Zacks Rank of #4 (Sell).

With respect to valuation, Booz Allen Hamilton is currently being traded at a Forward P/E ratio of 15.21. This valuation marks a discount compared to its industry average Forward P/E of 20.02.

Meanwhile, BAH's PEG ratio is currently 1.52. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Consulting Services stocks are, on average, holding a PEG ratio of 1.25 based on yesterday's closing prices.

The Consulting Services industry is part of the Business Services sector. This industry currently has a Zacks Industry Rank of 170, which puts it in the bottom 32% of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Vital Farms (VITL - Free Report) closed the most recent trading day at $41.98, moving +1.01% from the previous trading session. The stock outpaced the S&P 500's daily loss of 0.16%. Elsewhere, the Dow gained 0.44%, while the tech-heavy Nasdaq lost 0.76%.

Heading into today, shares of the company had lost 11.69% over the past month, lagging the Consumer Staples sector's loss of 3.79% and the S&P 500's gain of 1.14%.

The investment community will be closely monitoring the performance of Vital Farms in its forthcoming earnings report. In that report, analysts expect Vital Farms to post earnings of $0.29 per share. This would mark year-over-year growth of 81.25%. In the meantime, our current consensus estimate forecasts the revenue to be $191.08 million, indicating a 31.78% growth compared to the corresponding quarter of the prior year.

For the full year, the Zacks Consensus Estimates are projecting earnings of $1.37 per share and revenue of $772.03 million, which would represent changes of +16.1% and +27.33%, respectively, from the prior year.

Investors should also take note of any recent adjustments to analyst estimates for Vital Farms. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 1.19% upward. Right now, Vital Farms possesses a Zacks Rank of #3 (Hold).

Looking at its valuation, Vital Farms is holding a Forward P/E ratio of 30.42. This indicates a premium in contrast to its industry's Forward P/E of 15.51.

The Food - Miscellaneous industry is part of the Consumer Staples sector. This industry, currently bearing a Zacks Industry Rank of 195, finds itself in the bottom 22% echelons of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow VITL in the coming trading sessions, be sure to utilize Zacks.com.

In the latest close session, DaVita HealthCare (DVA - Free Report) was up +2.19% at $126.62. This move outpaced the S&P 500's daily loss of 0.16%. Meanwhile, the Dow experienced a rise of 0.44%, and the technology-dominated Nasdaq saw a decrease of 0.76%.

The stock of kidney dialysis provider has fallen by 5.38% in the past month, lagging the Medical sector's gain of 1.54% and the S&P 500's gain of 1.14%.

Investors will be eagerly watching for the performance of DaVita HealthCare in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on October 29, 2025. In that report, analysts expect DaVita HealthCare to post earnings of $3.29 per share. This would mark year-over-year growth of 27.03%. Meanwhile, our latest consensus estimate is calling for revenue of $3.4 billion, up 4.27% from the prior-year quarter.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $10.93 per share and revenue of $13.46 billion, indicating changes of +12.91% and +5.01%, respectively, compared to the previous year.

It is also important to note the recent changes to analyst estimates for DaVita HealthCare. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Currently, DaVita HealthCare is carrying a Zacks Rank of #3 (Hold).

With respect to valuation, DaVita HealthCare is currently being traded at a Forward P/E ratio of 11.34. This denotes a discount relative to the industry average Forward P/E of 21.14.

It is also worth noting that DVA currently has a PEG ratio of 0.89. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Outpatient and Home Healthcare industry had an average PEG ratio of 1.88 as trading concluded yesterday.

The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. With its current Zacks Industry Rank of 36, this industry ranks in the top 15% of all industries, numbering over 250.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow DVA in the coming trading sessions, be sure to utilize Zacks.com.

In the latest close session, Sunoco LP (SUN - Free Report) was up +1.13% at $50.82. This change outpaced the S&P 500's 0.16% loss on the day. Elsewhere, the Dow gained 0.44%, while the tech-heavy Nasdaq lost 0.76%.

The stock of master limited partnership has risen by 0.52% in the past month, leading the Oils-Energy sector's loss of 0.37% and undershooting the S&P 500's gain of 1.14%.

The investment community will be closely monitoring the performance of Sunoco LP in its forthcoming earnings report. The company is scheduled to release its earnings on November 5, 2025. On that day, Sunoco LP is projected to report earnings of $1.66 per share, which would represent year-over-year growth of 738.46%. Meanwhile, the latest consensus estimate predicts the revenue to be $5.58 billion, indicating a 2.94% decrease compared to the same quarter of the previous year.

Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $5.54 per share and revenue of $21.97 billion. These totals would mark changes of -7.67% and -3.18%, respectively, from last year.

Investors should also take note of any recent adjustments to analyst estimates for Sunoco LP. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. As of now, Sunoco LP holds a Zacks Rank of #3 (Hold).

From a valuation perspective, Sunoco LP is currently exchanging hands at a Forward P/E ratio of 9.07. This denotes a discount relative to the industry average Forward P/E of 17.15.

The Oil and Gas - Refining and Marketing - Master Limited Partnerships industry is part of the Oils-Energy sector. At present, this industry carries a Zacks Industry Rank of 99, placing it within the top 41% of over 250 industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow SUN in the coming trading sessions, be sure to utilize Zacks.com.

Humacyte, Inc. (HUMA - Free Report) closed the most recent trading day at $1.79, moving +1.7% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.16%. At the same time, the Dow added 0.44%, and the tech-heavy Nasdaq lost 0.76%.

Heading into today, shares of the company had gained 15.03% over the past month, outpacing the Medical sector's gain of 1.54% and the S&P 500's gain of 1.14%.

Investors will be eagerly watching for the performance of Humacyte, Inc. in its upcoming earnings disclosure. The company's upcoming EPS is projected at -$0.17, signifying a 48.48% increase compared to the same quarter of the previous year.

For the full year, the Zacks Consensus Estimates project earnings of -$0.35 per share and a revenue of $3.51 million, demonstrating changes of +66.67% and 0%, respectively, from the preceding year.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Humacyte, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. As of now, Humacyte, Inc. holds a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 94, putting it in the top 39% of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of American Depositary Shares (“ADS” or “ADSs”) of WPP plc (NYSE: WPP) between February 27, 2025 and July 8, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025.

SO WHAT: If you purchased WPP plc ADSs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the WPP plc class action, go to https://rosenlegal.com/submit-form/?case_id=46121 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of WPP’s media arm; notably, that it was not truly equipped to handle the ongoing macroeconomic challenges while competing effectively and had instead begun to lose significant market share to its competitors. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the WPP plc class action, go to https://rosenlegal.com/submit-form/?case_id=46121 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

BlackRock entwickelt Technologie, um Geldanlagen digital abzubilden.
CEO Larry Fink will damit Investieren günstiger und fairer machen.
Tokenisierung könnte die Finanzwelt dauerhaft verändern und vielen neue Chancen bieten.

BlackRock, der größte Vermögensverwalter der Welt, möchte die Finanzwelt umkrempeln. Das Unternehmen arbeitet daran, klassische Geldanlagen wie Aktienfonds oder Immobilien in digitale Form zu bringen – sogenannte Token. Was kompliziert klingt, könnte das Investieren einfacher, günstiger und zugänglicher machen als je zuvor.

BlackRock plant den großen Sprung in die digitale Finanzwelt
Der weltgrößte Vermögensverwalter BlackRock will traditionelle Anlagen wie Fonds oder Immobilien digital abbilden. Das erklärte CEO Larry Fink während der Präsentation der Quartalsergebnisse. Das Unternehmen arbeitet an einer eigenen Technologie, die sogenannte Tokenisierung ermöglichen soll. Dabei wird ein Vermögenswert – etwa ein Fonds – in digitale Einheiten umgewandelt, die auf einer Blockchain gespeichert sind.

🚨BlackRock CEO Larry Fink says “Everything will be tokenized!” 🌐💥#XRP #XRPCommunity pic.twitter.com/FYOVRI7o7P

— BULLRUNNERS (@BullrunnersHQ) October 14, 2025

Fink sieht darin eine große Chance. Durch Token könnten Anleger einfacher, schneller und mit weniger Gebühren investieren. Besonders bei klassischen Fonds, sogenannten ETFs (Exchange Traded Funds), könnte das laut ihm die Zugänglichkeit für alle erhöhen. Mit über 13 Billionen US-Dollar an verwaltetem Vermögen hat BlackRock die Mittel, diese Entwicklung maßgeblich voranzutreiben.

Was Tokenisierung überhaupt bedeutet
Tokenisierung heißt, dass reale Werte – zum Beispiel Aktien, Immobilien oder Anleihen – als digitale Token auf einer Blockchain dargestellt werden. Diese Token stehen symbolisch für das echte Eigentum. So können Werte leichter übertragen und verwaltet werden, ohne dass viele Zwischenhändler nötig sind.

Laut Larry Fink ist genau das der Vorteil: Wenn weniger Vermittler beteiligt sind, sinken die Gebühren. Dadurch könnten etwa Immobilienkäufe günstiger werden. Außerdem ließe sich Eigentum einfacher teilen – ein Haus könnte dann theoretisch von vielen Personen gemeinsam digital besessen werden, ohne komplizierte Verträge.

BlackRock arbeitet mit großen Finanzplattformen zusammen
Damit die Tokenisierung funktioniert, muss sie mit bestehenden Finanzsystemen verbunden werden. BlackRock führt deshalb Gespräche mit führenden Anbietern digitaler Finanzlösungen. Ziel ist, dass Anleger ihre digitalen Anteile sicher in sogenannten Wallets (digitalen Geldbörsen) halten können.

Fink gilt schon seit Jahren als einer der größten Befürworter dieser Technologie. Bereits 2022 sagte er, dass die Zukunft der Finanzmärkte in der Tokenisierung liegt. Jetzt scheint es ernst zu werden – und BlackRock will nicht warten, bis andere den Schritt gehen.

Les hier, wieso einige Experten bei BTC noch dieses Jahr eine Rally bis 250k sehen.

Neue Möglichkeiten für Anleger – besonders für junge Menschen
BlackRock testet den Wandel bereits praktisch. Der firmeneigene BUIDL-Fonds (USD Institutional Digital Liquidity Fund) ist einer der größten digitalisierten Fonds weltweit, mit einem Volumen von fast drei Milliarden US-Dollar. Er wird gemeinsam mit dem Blockchain-Unternehmen Securitize betrieben, an dem BlackRock selbst beteiligt ist.

Fink betonte, dass vor allem junge Menschen schon heute mit digitalen Vermögenswerten umgehen. Tokenisierte Fonds könnten ihnen helfen, frühzeitig für die Zukunft und den Ruhestand vorzusorgen. Für viele könnte das der Einstieg in eine neue Form der Geldanlage sein – einfach, transparent und ohne hohe Einstiegshürden.

BlackRock will die Regeln der Finanzwelt neu schreiben
Neben der Tokenisierung ist BlackRock schon heute ein Schwergewicht im Bereich digitaler Investments. Die Firma bietet die größten börsengehandelten Fonds (ETFs) für Bitcoin und Ethereum an – zusammen verwalten sie über 110 Milliarden US-Dollar. Diese Erfahrung mit digitalen Vermögenswerten gibt BlackRock einen Vorsprung gegenüber klassischen Banken.

Hier kommst du zu unserer detaillierten Prognose für Bitcoin.

Laut Fink steckt das Unternehmen aktuell viel Zeit und Geld in die Entwicklung eigener Technologien. Er kündigte an, dass es in den kommenden Jahren „spannende Ankündigungen“ geben werde. Sein Ziel sei klar: BlackRock wolle eine führende Rolle in einer neuen, vollständig digitalisierten Finanzwelt einnehmen – und so den Zugang zu Investitionen für alle öffnen.

Vollständig digitalisiert wird zukünftig auch das  Mining von Kryptowährung ablaufen, und zwar bei PepeNode! So gehts direkt in die Zukunft. Was BlackRock für Banken und Institutionen macht, können Investoren bei PepeNode in ähnlicher Weise ebenfalls umsetzen.

PepeNode: Wo Spaß, Strategie und Memes aufeinandertreffen
PepeNode ist kein gewöhnlicher Coin – hier wird Mining zum Spiel. Statt einfach nur zu kaufen und zu warten, können Nutzer eigene virtuelle Serverräume aufbauen, Nodes sammeln und ihr Setup verbessern. So entsteht ein Mix aus Game, Strategie und Krypto, der nicht nur spannend ist, sondern auch echtes Potenzial bietet – ganz ohne teure Hardware oder komplizierte Technik.

Hier kommst du zu einer langfristigen Prognose zu PepeNode!

Pepenode Presale
Spiel mit, aber bleib schlau
PepeNode macht Krypto unterhaltsam: Wer mitmacht, kann durch clevere Kombinationen und etwas Glück mehr $PEPENODE verdienen und auf den Leaderboards aufsteigen. Doch klar ist auch – es bleibt ein Memecoin. Das heißt: Spaß ja, aber bitte mit Köpfchen. Wer das Risiko versteht, hat hier die Chance, Teil eines verrückten, aber lohnenden Krypto-Experiments zu werden.

Jetzt rechtzeitig einsteigen und PEPENODE im Presale kaufen.

Hinweis: Investieren ist spekulativ. Bei der Anlage ist Ihr Kapital in Gefahr. Diese Website ist nicht für die Verwendung in Rechtsordnungen vorgesehen, in denen der beschriebene Handel oder die beschriebenen Investitionen verboten sind, und sollte nur von Personen und auf gesetzlich zulässige Weise verwendet werden. Ihre Investition ist in Ihrem Land oder Wohnsitzstaat möglicherweise nicht für den Anlegerschutz geeignet. Führen Sie daher Ihre eigene Due Diligence durch. Diese Website steht Ihnen kostenlos zur Verfügung, wir erhalten jedoch möglicherweise Provisionen von den Unternehmen, die wir auf dieser Website anbieten.

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

In brief
Bitcoin gained against Ethereum as Trump’s latest tariff threat weighed on markets.
Despite recently losing ground, Ethereum is still outperforming Bitcoin this year.
Some analysts foresee an altcoin rally, while others are doubtful.
Ethereum surged against Bitcoin on its way toward a peak of nearly $5,000 this summer, but the reigning cryptocurrency reasserted itself this weekend, as a tit-for-tat between the U.S. and China over tariffs and trade sent economic concerns flaring for a second time this year.

Although the price of both assets fell in U.S. dollar terms, Bitcoin’s value increased relative to Ethereum, to the point that a single Bitcoin was worth nearly 30 Ethereum on Friday, according to Yahoo Finance. On Tuesday, a single Bitcoin had weakened to around 27.7 Ethereum.

As China sanctioned U.S. components of a South Korean shipping company, and U.S. Treasury Scott Bessent suggested the economy of America’s largest trading partner was “weak,” it appeared that President Donald Trump’s tariff threat on Friday could prompt another standoff ahead.

Pedro Lapenta, head of research at crypto asset manager Hashdex, told Decrypt that Ethereum’s recent underperformance against Bitcoin “reflects shifting macro narratives more than fundamentals.” That includes a so-called debasement trade, which is also benefiting Bitcoin more, as investors seek shelter from potential currency devaluation.

“Bitcoin naturally captures that hedge demand first,” he said. “But the structural story for Ethereum remains strong, anchored in the rise of regulated stablecoins, tokenization, and institutional adoption of on-chain finance.”

At its weakest this year, a single Bitcoin was worth 23.7 Ethereum, which coincided with the smaller asset’s climb to a new all-time high of $4,956 in August, according to CoinGecko.

Throughout most of April, however, a single Bitcoin was worth at least 50 ETH, reflecting one of its strongest periods against the smaller asset this year, while the Trump administration managed expectations around “reciprocal” tariffs.

At the time, Bitcoin was the only digital asset that appeared to benefit from perceived shifts in the global geopolitical order or risk, with some analysts comparing its performance to gold. 

Between the Federal Reserve’s calculus on interest rate cuts and an ongoing government shutdown, the Trump administration’s trade moves are just one factor shaping markets. But there are also developments specific to the crypto industry that one should consider, according to Juan Leon, senior investment strategist at Bitwise.

He said Ethereum’s recent run stems from investor excitement toward the emergence of Ethereum treasury firms and the passage of stablecoin legislation. Along with a supportive regulatory environment, he said the setup “holds promise for an altcoin rally” into next year.

Bitcoin has outperformed Ethereum for several years, but the smaller asset’s price has increased relatively more this year, despite losing most ground gained against Bitcoin in recent weeks.

In market cycles past, Bitcoin’s peak has been followed by a sustained period of strength for cryptocurrencies like Ethereum, often called an “altcoin season.”

TD Cowen analyst Lance Vitanza told Decrypt that he’s “never been a believer in this or any ‘altcoin season,’” arguing that only a handful of tokens are likely to survive as legitimate tech.

That said, he believes Ethereum “represents real technology” and is likely to play a meaningful role in decentralized finance, such as the potential tokenization of trillions of dollars in assets. As a result, he said Ethereum “could appreciate meaningfully over time.”

Vitanza said that Ethereum will always be more volatile than Bitcoin, and there may be some months where the smaller asset performs better. But Vitanza said “would be surprised if the outperformance, if any, were to persist” more than a few months.

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

Solmate has completed a discounted acquisition of SOL to power UAE operations, the Solana Foundation has gained board nomination rights, and Ark Invest has disclosed an 11.5% stake as institutional exposure has expanded.

Bitcoin supply has tightened as spot ETFs have absorbed coins into long-term custody, with IBIT holding 800,000+ BTC and exchange balances having fallen by 90,000 BTC. U.S. government wallets have shifted 667 BTC and hold over 200,000 BTC, shaping liquidity and volatility.

Pi Coin’s money inflow is rising, but RSI-led momentum is weakening, creating a conflicting setup.The falling wedge pattern suggests a possible reversal if PI breaks above $0.29.A drop below $0.15 could invalidate the bullish setup and extend the correction.Pi Coin has held stronger than most major cryptocurrencies as the crypto market corrected by over 3% today. While Bitcoin, Ethereum, and BNB dropped between 3% and 12%, the Pi Coin price slipped only 1.5% in the past 24 hours — showing rare resilience. Yet traders are now facing a puzzle: two opposing chart signals that could determine whether the next move brings recovery or another leg down.

For now, Pi Coin’s structure is caught between cautious optimism and fading strength.

Sponsored

Sponsored

Two Signals, One Uncertain OutcomePi Coin’s chart presents an interesting clash between buying strength and momentum weakness — two signals that usually guide short-term price direction.

The Money Flow Index (MFI), which tracks money flowing in and out of the asset, has been climbing even as the Pi Coin price made a lower low between August 1 and October 9. This is typically seen as a bullish divergence, suggesting that while prices fell, fresh buying quietly entered the market. It reflects growing retail interest — the kind of slow accumulation that often forms the base for a rebound.

Pi Coin Showing Money Flow: TradingViewWant more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.

However, between October 6 and October 13, PI’s Relative Strength Index (RSI) — a measure of market momentum — painted a hidden bearish divergence. Prices made a lower high while RSI made a higher high, indicating that buying momentum is fading even as short-term recovery attempts occur.

Pi Coin RSI Showing Bearishness: TradingViewSponsored

Sponsored

Rather than contradicting each other completely, these two readings could be showing different stages of the same process: MFI points to early accumulation, while RSI warns that recovery may face resistance before stronger confirmation. For traders, that means the setup still leans neutral — with a slight tilt toward caution until the next breakout or breakdown confirms direction.

More on this in the next section, where we discuss the Pi Coin price action.

Pi Coin Price Setup Reveals A Falling WedgeFrom a structural perspective, the Pi Coin price trades inside a falling wedge — a pattern that often hints at a possible bullish reversal on a daily chart.

To confirm strength, a daily Pi Coin price candle must move above $0.29, which would indicate a breakout from the wedge and likely attract new buying volume.

Pi Coin Price Analysis: TradingViewHowever, if we just look at the near-term history, a rebound similar to September 22, when PI jumped 57% from $0.18 to $0.29, could repeat. This implies short-term targets around $0.24–$0.25, with an extended move toward $0.29 possible if momentum picks up. And breaking $0.29 cleanly would mean bullish strength for the Pi Coin price.

At the time of writing, Pi Coin (PI) trades near $0.21, with strong support around $0.18 and $0.15. A clean daily close below $0.15 would break the wedge to the downside, invalidating the bullish setup.

For now, PI remains one of the few coins outperforming the market but still walking a fine line. Whether the MFI-led accumulation wins or RSI-led weakness extends the pullback, the falling wedge will be the final judge of where the Pi Coin price goes next.

Disclaimer

In line with the Trust Project guidelines, this price analysis article is for informational purposes only and should not be considered financial or investment advice. BeInCrypto is committed to accurate, unbiased reporting, but market conditions are subject to change without notice. Always conduct your own research and consult with a professional before making any financial decisions. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

In a landmark financial enforcement move, the U.S. Department of the Treasury has initiated significant sanctions and asset forfeitures aimed at transnational criminal syndicates. Central to this effort is the attempt to seize 127,271 bitcoins, currently estimated to be worth approximately $12 billion.

TLDR

Shibarium has reactivated its Plasma Bridge for BONE with enhanced security measures.
The new blacklisting functionality will block suspicious addresses at the bridge layer.
Shibarium has added a 7-day withdrawal delay for all BONE transactions to prevent fraud.
The security improvements follow a flash loan attack in September 2025, which resulted in a $4.1 million loss.
Shiba Inu developers quickly responded to the attack and successfully reestablished the Plasma Bridge with added protections.

Shibarium has reactivated its Plasma Bridge for BONE following a recent security breach. This follows a flash loan attack in September 2025, which resulted in a $4.1 million theft. The Shiba Inu team has worked to enhance the platform’s security features, ensuring a safer experience for users.

Shibarium Brings Enhanced Security with Blacklisting Functionality
Shibarium’s Plasma Bridge now features blacklisting functionality, designed to enhance security. This new feature allows Shiba Inu to block suspicious addresses at the bridge layer.

“We are pleased to share that the Plasma Bridge is back online for BONE,” the team stated in a blog post.

The new system offers an additional layer of fraud protection by flagging and blocking addresses that appear suspicious. With this proactive approach, Shiba Inu aims to prevent future attacks targeting the ecosystem. The team is committed to creating a safer environment for BONE transactions across the network.

BONE Token Withdrawals Now Have 7-Day Delay for Extra Protection
Along with blacklisting, Shibarium has implemented a 7-day withdrawal delay for all BONE transactions. This delay gives security teams time to monitor and address any suspicious activities. The Shiba Inu team explained that the added delay will not affect user access but will provide an extra layer of protection against fraud.

The withdrawal delay reinforces Shibarium’s fraud-resistance measures, allowing the team to detect any anomalies. Security teams will use this buffer to investigate potential threats and prevent future losses.

“Plasma’s strength is fraud-resistance. The delay reinforces that property and provides a practical response window if anomalies are detected,” the Shib team added.

Shiba Inu’s response to the September hack has been swift, with the platform quickly recovering from the attack. After freezing the system, the team successfully reestablished the Plasma Bridge with enhanced security. As a result, Shibarium users can now securely bridge BONE tokens between Ethereum and Shibarium.